The arrival of Retatrutide in the nation is sparking significant anticipation within the obesity community. This innovative dual agonist – targeting both GLP-1 and GIP – offers a potentially new approach to tackling excess weight . Until recently, options have been limited for many, and Retatrutide represents a hopeful prospect for patients see